Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): May
5, 2005
Keryx
Biopharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
(State
or Other Jurisdiction of
Incorporation) |
000-30929
(Commission
File Number) |
13-4087132
(IRS
Employer Identification No.) |
750
Lexington Avenue
New
York, New York 10022
(Address
of Principal Executive Offices)
(212)
531-5965
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| £ |
Written
communications pursuant to Rule 425 under the Securities
Act. |
| £ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act. |
| £ |
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act. |
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act. |
Item
8.01. Other
Events
On May 5,
2005, Keryx Biopharmaceuticals, Inc. issued a press release announcing interim
results from a Phase II clinical study for KRX-101 (Sulodexide Gelcaps) for the
treatment of diabetic nephropathy. The data was presented by Dr. Edmund J.
Lewis, MD, on May 5, 2005, at the National Kidney Foundation Spring Clinical
Meeting in Washington, D.C. A copy of
such press release is being filed as Exhibit 99.1 to this report and is
incorporated herein by reference.
Item
9.01. Financial
Statements and Exhibits
(c) Exhibits
The
following exhibit is filed as a part of this report:
Exhibit
Number Description
99.1
Press
Release dated May 5, 2005
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Keryx
Biopharmaceuticals, Inc.
(Registrant)
Date: May
5, 2005
By: /s/
Ron Bentsur
Ron
Bentsur
Vice
President, Finance and Investor Relations
INDEX
TO EXHIBITS
Exhibit
Number Description
99.1 Press
Release dated May 5, 2005